Introduction: 431
Data fitting -In the kinetic simulations, the concentrations of chemical species ([E] , [S] , [I] , [P] , [ES] , [EI] ) over time were calculated using a system of ordinary differential equations for each reaction step ( Figure 4A ). Progress curves for each inhibitor concentration were fit to a five-parameter (k 1 , k -1 , k on , k off , k cat ) kinetic inhibition model using APPSPACK optimization software. APPSPACK is a generic solver for linearly-constrained optimization problems (Griffin and Kolda, 2006) .
Selectivity -SID 26681509 was assayed for inhibition against papain and cathepsins B,
G, K, S, and V. Papain from Carica papaya (Calbiochem 5125, 11 ng/mL), human cathepsin K (Calbiochem 342001, 35 ng/mL), human spleen cathepsin S (Calbiochem 219344, 40 ng/mL), and human cathepsin V (Calbiochem 219467, 39 ng/mL) were assayed using Z-Phe-Arg-AMC substrate at 20 µM, 20 µM, 15 µM, and 1 µM, respectively. Human liver cathepsin B (Calbiochem 219362, 65 ng/mL) was assayed using 15 µM Z-Arg-Arg-AMC substrate (Bachem I-1135) . Human neutrophil cathepsin G (Calbiochem 219373, 4.2 µg/mL) was assayed using 15 µM Suc-Ala-Ala-Pro-Phe-AMC substrate (Sigma S9761). All reactions were performed in 20 mM sodium acetate buffer containing 5 mM cysteine and 1 mM EDTA, pH 5.5. Reaction progress was monitored using the Envision microplate reader. IC 50 values were measured in triplicate.
Cytotoxicity -Human aortic endothelial cells were seeded in a Corning 3704 384-well white sterile tissue culture-treated microplate at 1000 cells/25 µL/well. The plate was This article has not been copyedited and formatted. The final version may differ from this version. centrifuged and incubated at 37 °C for 24 hr. SID 26681509 and doxorubicin positive control were then serially diluted in EGM-2 endothelial cell media (Lonza CC4176). Five µL each of these serial dilutions were added to the cells in triplicate, resulting in final concentrations of compound from 100 µM to 156 nM (0.17% DMSO). The plate was centrifuged and incubated at 37 °C for 24 hrs. Thirty µL CellTiter-Glo™ (Promega G7570) were added to each well and centrifuged. After 10 minutes, luminescence was measured using the Envision microplate reader.
Malaria assay -Eight two-fold serial dilutions of SID 26681509 in RPMI 1640 media (Invitrogen 11875) containing L-Glutamine, 50 mg/L hypoxanthine, 6 g/L HEPES, 0.5% Albumax II bovine serum (Invitrogen 11021), 0.225% sodium bicarbonate, and 1 µg/mL gentamicin were performed in Corning 3704 microplates. Adding 30 µL red blood cells infected with synchronized ring stage luciferase-expressing Plasmodium falciparum parasites at 0.5% parasitaemia and 4% hematocrit to 10 µL compound resulted in final concentrations tested of 50 µM to 1.5 nM. In addition, 30 µL normal red blood cells and 30 µL infected red blood cells were added to two control columns containing 10 µL media. The plates were incubated at 37 °C in a 92% humidity chamber with 5% CO 2 , 5% O 2 , and 90% N 2 for 48 hrs to allow for two cycles of red blood cell rupture and invasion to take place. Forty µL BrightGlo™ (Promega E2610) were added to each well and centrifuged. After 5 minutes, luminescence was measured using the Envision microplate reader. 
Selectivity against papain and cathepsins B, G, K, S, and V -SID 26681509 was tested
for inhibitory activity against papain and human cathepsins B, G, K, L, S, and V ( Table 1) Table 2) . SID 26681509 inhibited papain and cathepsins B, K, S, and V with IC 50 values determined after one hour ranging from 618 nM to 8.442 µM.
As expected, SID 26681509 showed no inhibitory activity against the serine protease cathepsin G. The IC 50 values systematically decreased with time for each protease, demonstrating the slowbinding nature of the small molecule inhibitor. The qualitative order of the selectivity index is fairly insensitive to when the measurement was taken; however, the weak trends observed in the selectivity index data likely reflect the relative rates of slowly reversible inhibition of the enzyme. Thus, it would appear that the slowly reversible reaction proceeds faster for cathepsins V and S than for cathepsin L; whereas, it proceeds more slowly for papain.
This article has not been copyedited and formatted. The final version may differ from this version. Biological assays -SID 26681509 was found to be non-toxic to human aortic endothelial cells at 100 µM. The inhibitor also demonstrated a lack of toxicity to zebrafish in a live organism assay at 100 µM. SID 26681509 was active in an in vitro propagation assay against
Plasmodium falciparum with an IC 50 of 15.4 ± 0.6 µM ( Figure 5A) . Additionally, the thiocarbazate inhibitor was toxic toward Leishmania major promastigotes with an IC 50 of 12.5 ± 0.6 µM ( Figure 5B ). Finally, the active site Cys25 sulfur is in close proximity (3.289 Å) to the carbonyl carbon of the thiocarbazate. Although the contribution from covalent bonding between this carbon and sulfur cannot be directly assessed through our docking studies, the molecule sits in the proper orientation to achieve this covalent binding interaction ( Figure 7A ). As indicated above, however, we lack compelling evidence for covalent binding between the enzyme and SID 26681509.
Molecular docking of SID 26681509 in papain -

Discussion
Our kinetic analyses demonstrate that SID 26681509 is a highly potent and selective competitive inhibitor of human cathepsin L with slow binding and slow reversibility kinetics.
Molecular docking of SID 26681509 into the papain crystal structure revealed hydrophobic interactions within the S2 and S1′ subsites and hydrogen bonding interactions with Gln19, Cys25, Gly66, Asp158, and Trp177. These interactions share a high degree of similarity with the papain/CLIK-148 complex (Katunuma et al., 1999; Tsuge et al., 1999) .
With the exception of cathepsin K, the range of selectivity indexes of SID 26681509 decreased as the percent identity to cathepsin L increased. This may be due to the strong P2
This article has not been copyedited and formatted. The final version may differ from this version. demonstrates that the enzyme is recovering and the reaction is reversible. The rate of AMC release after 8820 s was 4.7 times greater than the initial release rate.
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